Table 3.
Means and standard deviations of the percentage of methylation detected at each CpG site in KD patients responding or not responding to intravenous immunoglobulin treatment.
| Gene | CpG sites | Methylation (%) | P value | |||||
|---|---|---|---|---|---|---|---|---|
| IVIG-nonresponsive patients (N = 13) | IVIG-responsive patients (N = 22) | |||||||
| Mean | SD | 95% CI | Mean | SD | 95% CI | |||
| FCGR2A | A | 80.06 | 4.51 | 77.33–82.79 | 80.94 | 5.55 | 78.48–83.40 | 0.6319 |
| B | 71.40 | 6.65 | 67.39–75.42 | 57.55 | 7.11 | 54.40–60.70 | <0.0001*** | |
| C | 72.93 | 5.64 | 69.52–76.34 | 68.40 | 5.09 | 66.15–70.66 | 0.0201* | |
| D | 69.46 | 4.72 | 66.60–72.31 | 66.85 | 5.28 | 64.50–69.19 | 0.1516 | |
| E | 67.65 | 4.43 | 64.97–70.33 | 57.90 | 3.03 | 56.56–59.25 | <0.0001*** | |
| F | 88.34 | 4.92 | 85.37–91.31 | 78.47 | 5.98 | 75.82–81.12 | <0.0001*** | |
| G | 68.38 | 5.71 | 64.93–71.83 | 68.95 | 5.48 | 66.52–71.38 | 0.7723 | |
| H | 55.32 | 9.42 | 49.63–61.02 | 36.38 | 6.33 | 33.57–39.19 | <0.0001*** | |
| I | 83.56 | 5.59 | 80.18–86.94 | 83.48 | 5.83 | 80.89–86.06 | 0.9650 | |
| J | 69.26 | 6.72 | 65.19–73.32 | 58.53 | 6.22 | 55.77–61.29 | <0.0001*** | |
| K | 71.30 | 6.92 | 67.12–75.48 | 65.27 | 6.68 | 62.31–68.24 | 0.0158* | |
The statistical significance * P < 0.05, *** P < 0.0001.